Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

Geahča maid

• Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
  Dahkki: Zarir F. Udwadia, et al.
  Almmustuhtton: (2021-04-01)
• Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting
  Dahkki: Reddy PK, et al.
  Almmustuhtton: (2022-05-01)
• Effects of the RNA-Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers—An MD Study
  Dahkki: Mauro Bringas, et al.
  Almmustuhtton: (2022-09-01)
• Evaluation of the effect of favipiravir on patients with COVID-19
  Dahkki: Alireza Kamali, et al.
  Almmustuhtton: (2023-02-01)
• Favipiravir: the hidden threat of mutagenic action
  Dahkki: O. P. Zhirnov, et al.
  Almmustuhtton: (2021-05-01)